Strong Year-End Performance
Q4 2024 saw an 8.3% underlying revenue growth with particularly strong performance in the US at 11.9% growth.
Successful Execution of 12-Point Plan
The 12-Point Plan is driving operational improvements, product innovation, and financial outcomes with 60 basis points of margin expansion and 95% cash conversion in 2024.
Record Installations of CORI Robotics
CORI robotic systems exceeded 1,000 global installations by year-end, with a record number of new placements in Q4 2024.
Advanced Wound Management Growth
The Advanced Wound Management segment delivered 12.2% growth in Q4, driven by bioactives and devices.
Innovation Driving Revenue
Over 60% of revenue growth in 2024 came from products launched in the last five years.